TY - JOUR
T1 - Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan
AU - Lin, Sung Yen
AU - Chen, Yi Ming
AU - Chen, Wei Ju
AU - Li, Chun Yi
AU - Ku, Chieh Ko
AU - Chen, Chung Hwan
AU - Chien, Li Nien
N1 - Funding Information:
This study was financially supported by Amgen Taiwan Limited. Wei-Ju Chen, Chun-Yi Li, and Chieh-Ko Ku (employed by Amgen Taiwan Limited) had disclosed potential financial conflict of interest. The funding received from Amgen Taiwan Limited is for academic research only and not for commercial purposes. The remaining authors (Sung-Yen Lin, Yi-Ming Chen, Chung-Hwan Chen, and Li-Nien Chien) declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher Copyright:
© 2022, International Osteoporosis Foundation and National Osteoporosis Foundation.
PY - 2022/12
Y1 - 2022/12
N2 - Summary: Treatment persistence was higher among the patients who initially received an anti-osteoporosis medication (AOM) with a long-dose-interval. Purpose: With long-dose-interval anti-osteoporosis medications (AOMs) available for osteoporosis management, it is important to evaluate persistence of any AOM as long as it is continuously used. The purpose of this study was to investigate the treatment pattern and persistence of AOMs, allowing for medication switch. Methods: This study was an observational retrospective cohort study using Taiwan’s National Health Insurance claims data. We selected patients who first initiated an AOM between January 1, 2013, and June 30, 2016. AOM therapy included alendronate, raloxifene, teriparatide, denosumab, zoledronate, and ibandronate; the latter three were categorized as long-dose-interval medications. Persistence was defined as continual prescription of any AOM at a given time point with a grace period of 45 days within which to obtain prescription refill. The competing risk model was used to examine the factors affecting patients switching their initial AOM. Results: During the study period, 126,539 patients with mean age of 75 years met the inclusion criteria; 85% were female. For initial AOM, 43.3%, 25.6%, 14.6%, 9.3%, 5.3%, and 1.9% of the patients received alendronate, denosumab, raloxifene, zoledronate, ibandronate, and teriparatide, respectively. During a mean 36-month follow-up, 29.6% of the patients who received at least two AOM pharmacy claims throughout the study period have ever switched their initial medication. Long-dose-interval medications, mainly denosumab and zoledronate, were the preferred choice for medication switch. Treatment persistence was higher in patients who initiated with long-dose-interval AOMs. Conclusion: The real-world data reveal long-dose-interval therapy as an initial treatment or at the first switch stage may improve management of persistent AOM treatment.
AB - Summary: Treatment persistence was higher among the patients who initially received an anti-osteoporosis medication (AOM) with a long-dose-interval. Purpose: With long-dose-interval anti-osteoporosis medications (AOMs) available for osteoporosis management, it is important to evaluate persistence of any AOM as long as it is continuously used. The purpose of this study was to investigate the treatment pattern and persistence of AOMs, allowing for medication switch. Methods: This study was an observational retrospective cohort study using Taiwan’s National Health Insurance claims data. We selected patients who first initiated an AOM between January 1, 2013, and June 30, 2016. AOM therapy included alendronate, raloxifene, teriparatide, denosumab, zoledronate, and ibandronate; the latter three were categorized as long-dose-interval medications. Persistence was defined as continual prescription of any AOM at a given time point with a grace period of 45 days within which to obtain prescription refill. The competing risk model was used to examine the factors affecting patients switching their initial AOM. Results: During the study period, 126,539 patients with mean age of 75 years met the inclusion criteria; 85% were female. For initial AOM, 43.3%, 25.6%, 14.6%, 9.3%, 5.3%, and 1.9% of the patients received alendronate, denosumab, raloxifene, zoledronate, ibandronate, and teriparatide, respectively. During a mean 36-month follow-up, 29.6% of the patients who received at least two AOM pharmacy claims throughout the study period have ever switched their initial medication. Long-dose-interval medications, mainly denosumab and zoledronate, were the preferred choice for medication switch. Treatment persistence was higher in patients who initiated with long-dose-interval AOMs. Conclusion: The real-world data reveal long-dose-interval therapy as an initial treatment or at the first switch stage may improve management of persistent AOM treatment.
KW - Anti-osteoporosis medication
KW - Claim-based data
KW - Persistence
KW - Treatment pattern
UR - http://www.scopus.com/inward/record.url?scp=85134235747&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134235747&partnerID=8YFLogxK
U2 - 10.1007/s11657-022-01125-6
DO - 10.1007/s11657-022-01125-6
M3 - Article
C2 - 35840845
AN - SCOPUS:85134235747
SN - 1862-3522
VL - 17
JO - Archives of Osteoporosis
JF - Archives of Osteoporosis
IS - 1
M1 - 94
ER -